Literature DB >> 1623479

Results of surgical treatment of 1028 cervical cancers studied with volumetry.

E Burghardt1, J Baltzer, A H Tulusan, J Haas.   

Abstract

BACKGROUND AND METHODS: The clinical staging system of cervical cancer according to the International Federation of Gynecology and Obstetrics (FIGO) entails a large measure of subjectivity. This study analyzed the results of 1028 patients with cervical cancer at three reference centers. All patients had radical surgery, and all surgical specimens were processed as histologic giant sections with precise volumetry of the tumor.
RESULTS: The interpretation of the histologic findings of parametrial invasion, vascular involvement, and lymph node involvement was found to differ somewhat among the three centers. However, all these findings were associated with tumor size. Survival rates correlated more consistently with tumor volume than with clinical or histologic stage. Five-year survival rates ranged from 91% for patients with tumors smaller than 2.5 cm3 to 70% for those with tumors 10-50 cm3. The 5-year survival rate of 24 patients with tumors larger than 50 cm3 (71% of whom had lymph nodes with positive findings) was 48%. Survival rates were identical among the three centers for patients with tumors smaller than 10 cm3, despite different degrees of surgical radicality. In contrast, more radical surgery was associated with significantly better survival rates in patients with larger tumors.
CONCLUSIONS: The results of this study indicate that volumetry of the tumor permits a more accurate assessment of therapeutic results in patients with cervical cancer than does the FIGO classification. Pretherapeutic assessment of tumor volume is possible with magnetic resonance imaging. It seems that maximum parametrial resection is not necessary for patients with smaller tumors (smaller than 10 cm3), but truly radical surgery in patients with bulky tumors achieves better results than those usually expected in Stage IIb cervical cancer and at least comparable to those of radiation therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1623479     DOI: 10.1002/1097-0142(19920801)70:3<648::aid-cncr2820700318>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  What is your diagnosis?

Authors:  Cemil Yaman; Dietmar Haas; Radec Chvatal; Peter Oppelt
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-09-01

2.  Unusual Metastasis from Carcinoma Cervix.

Authors:  Virendra Bhandari; Mehlam Kausar; Ayush Naik; Manika Batra
Journal:  J Obstet Gynaecol India       Date:  2015-05-09

3.  Splenic Metastasis from Cancer of Uterine Cervix-a Rare Case.

Authors:  Jagannath Dixit; Noor Mohammed; Preethi Shetty
Journal:  Indian J Surg Oncol       Date:  2016-10-18

Review 4.  [Uterine cervical cancer : preoperative staging with magnetic resonance imaging].

Authors:  F Collettini; B Hamm
Journal:  Radiologe       Date:  2011-07       Impact factor: 0.635

5.  Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy.

Authors:  Dae Woo Lee; Young Tae Kim; Jae Hoon Kim; Sunghoon Kim; Sang Wun Kim; Eun Ji Nam; Jae Wook Kim
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

6.  Fluorescence spectroscopy for diagnostic differentiation in uteri's cervix biopsies with cervical/vaginal atypical cytology.

Authors:  Ademir Barianni Rodero; Landulfo Silveira; David Augusto Rodero; Roberto Racanicchi; Marcos Tadeu T Pacheco
Journal:  J Fluoresc       Date:  2008-03-25       Impact factor: 2.217

7.  Hep Par 1 expression in carcinoma of the cervix: implications for diagnosis and prognosis.

Authors:  T P Thamboo; A Wee
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

8.  Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.

Authors:  Hiroko Machida; Aida Moeini; Marcia A Ciccone; Sayedamin Mostofizadeh; Tsuyoshi Takiuchi; Laurie L Brunette; Lynda D Roman; Koji Matsuo
Journal:  Am J Clin Oncol       Date:  2018-09       Impact factor: 2.339

9.  Volumetric and MGMT parameters in glioblastoma patients: survival analysis.

Authors:  Georgios Iliadis; Vassiliki Kotoula; Athanasios Chatzisotiriou; Despina Televantou; Anastasia G Eleftheraki; Sofia Lambaki; Despina Misailidou; Panagiotis Selviaridis; George Fountzilas
Journal:  BMC Cancer       Date:  2012-01-03       Impact factor: 4.430

10.  3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital experience.

Authors:  Su-Ping Liu; Xiao Huang; Gui-Hao Ke; Xiao-Wei Huang
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.